Pacific Biosciences of California Inc (STU:P09)
€ 2.319 0.068 (3.02%) Market Cap: 639.11 Mil Enterprise Value: 1.02 Bil PE Ratio: 0 PB Ratio: 1.39 GF Score: 57/100

Pacific Biosciences of California Inc at UBS Global Healthcare Virtual Conference Transcript

May 25, 2021 / 03:00PM GMT
Release Date Price: €20.93 (-0.05%)
Daniel Gregory Brennan
UBS Investment Bank, Research Division - Senior Equity Research Analyst of Healthcare Life Sciences

Good morning. Welcome to Day 2 of the UBS Healthcare Conference. I'm Dan Brennan. I cover life science tools, diagnostics, pharma services. And really pleased to be joined with me here on the virtual stage with senior management of Pacific Biosciences. We have the CFO, Susan Kim, with Todd Friedman, Director of IR.

Listen, I don't cover PacBio, but I've known the company for many years, obviously, doing terrifically well with some new product introductions, and the story has really evolved here under new management. I thought before we kick off with Susan in the Q&A, I think we're going to go first to a short slide presentation that Susan is going to walk through maybe some overview on PacBio, and then we'll get into it. So with that, Susan, welcome, and really pleased to have you here.

Susan G. Kim
Pacific Biosciences of California, Inc. - CFO

Thank you, Dan. It's very nice to see you. I'm very excited to be here to share

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot